Document:

EX-10.2

 Exhibit 10.2 
 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 Execution Copy 
 MANUFACTURING AND SUPPLY AGREEMENT 

by and between 

ETHYPHARM S.A. 
 and 
 AMPIO PHARMACEUTICALS, INC. 

* * * 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”.
A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

  

 TABLE OF CONTENTS 

 
  

							
	 	  	 	  	Page	 
	 ARTICLE 1 DEFINITIONS
	  	 	4	  
		
	 ARTICLE 2 APPOINTMENT OF MANUFACTURER
	  	 	8	  
	 2.1
	  	Requirements	  	 	8	  
	 2.2
	  	Third Party Manufacturer	  	 	8	  
	 2.3
	  	Joint Manufacturing Committee	  	 	8	  
		
	 ARTICLE 3 REGULATORY AND QUALITY UNDERTAKINGS
	  	 	9	  
	 3.1
	  	Regulatory	  	 	9	  
	 3.2
	  	Import and Packaging	  	 	9	  
	 3.3
	  	Change in Specifications	  	 	9	  
	 3.4
	  	Advertising, Promotional Materials, and Public Statements	  	 	10	  
	 3.5
	  	Product Complaints and Adverse Drug Experiences	  	 	10	  
	 3.6
	  	Facility Maintenance; Inspection; Reports	  	 	10	  
	 3.7
	  	Filing Requirements and Maintenance	  	 	10	  
	 3.8
	  	Product Recall	  	 	11	  
	 3.9
	  	Quality Agreement	  	 	11	  
		
	 ARTICLE 4 FORECAST, ORDER, SUPPLY PRICE, SUPPLY INTERRUPTION
	  	 	12	  
	 4.1
	  	Forecast Reports	  	 	12	  
	 4.2
	  	Product Orders	  	 	12	  
	 4.3
	  	Batch Sizes of Product	  	 	12	  
	 4.4
	  	Inventories	  	 	12	  
	 4.5
	  	Supply Price of the Product	  	 	13	  
	 4.6
	  	Supply Interruption	  	 	13	  
	 4.7
	  	Deficiency Notice	  	 	14	  
	 4.8
	  	Determination of Deficiency	  	 	14	  
	 4.9
	  	Rejection for Deficiency	  	 	15	  
		
	 ARTICLE 5 WARRANTIES AND COVENANTS
	  	 	15	  
	 5.1
	  	Certain Representations and Warranties of Ethypharm	  	 	15	  
	 5.2
	  	Certain Representations and Warranties of Ampio	  	 	15	  
	 5.3
	  	Certain Covenants of Ampio	  	 	16	  
	 5.4
	  	Certain Covenants of Ethypharm	  	 	16	  
	 5.5
	  	Storage	  	 	16	  

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”.
A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

  

							
	 5.6
	  	Representation and Warranties with Regard to Status	  	 	16	  
	 5.7
	  	Compliance with Specifications and cGMP	  	 	16	  
	 5.8
	  	Limitation of Warranty	  	 	17	  
		
	 ARTICLE 6 INDEMNIFICATION AND LIMITATION OF LIABILITY
	  	 	17	  
	 6.1
	  	Ethypharm’s Indemnification Obligations	  	 	17	  
	 6.2
	  	Ampio’s Indemnification Obligations	  	 	17	  
	 6.3
	  	Indemnification Procedures	  	 	17	  
	 6.4
	  	Limitation of Liability	  	 	18	  
		
	 ARTICLE 7 INSURANCE
	  	 	18	  
		
	 ARTICLE 8 CONFIDENTIALITY
	  	 	19	  
	 8.1
	  	Treatment of Confidential Information	  	 	19	  
	 8.2
	  	Limits on Disclosure	  	 	19	  
		
	 ARTICLE 9 TERM AND TERMINATION
	  	 	20	  
	 9.1
	  	Term	  	 	20	  
	 9.2
	  	Termination for Breach	  	 	20	  
	 9.3
	  	Termination for Bankruptcy	  	 	20	  
	 9.4
	  	Withdrawal of Regulatory Approval and NDA	  	 	20	  
	 9.5
	  	No Waiver of Termination Rights	  	 	20	  
		
	 ARTICLE 10 FORCE MAJEURE
	  	 	21	  
	 10.1
	  	Effects of Force Majeure	  	 	21	  
	 10.2
	  	Notice of Force Majeure	  	 	21	  
		
	 ARTICLE 11 Miscellaneous
	  	 	21	  
	 11.1
	  	Dispute Resolution	  	 	21	  
	 11.2
	  	Independent Contractors	  	 	22	  
	 11.3
	  	Assignment	  	 	22	  
	 11.4
	  	Governing Law	  	 	22	  
	 11.5
	  	No Implied Waiver	  	 	22	  
	 11.6
	  	Notice	  	 	22	  
	 11.7
	  	Amendments	  	 	23	  
	 11.8
	  	Counterparts	  	 	23	  
	 11.9
	  	Interpretation	  	 	24	  
	 11.10
	  	Entire Agreement	  	 	24	  
	 11.11
	  	Benefit; Binding Effect	  	 	24	  
	 11.12
	  	Survival	  	 	24	  
	 11.13
	  	Further Assurances	  	 	24	  
	 11.14
	  	Severability	  	 	24	  
	 11.15
	  	Use of Names; Publicity	  	 	25	  
		  		  			

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”.
A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

  

 MANUFACTURING AND SUPPLY AGREEMENT 

THIS MANUFACTURING AND SUPPLY AGREEMENT (the “Agreement”), dated as of September 10, 2012 (the
“Effective Date”), is entered into by and between ETHYPHARM S.A., a corporation organized under the laws of France with an address at 194 Bureaux de la Colline, F92213 Saint-Cloud, France (“Ethypharm”), and AMPIO
PHARMACEUTICALS, INC., a corporation organized under the laws of the state of Delaware with an address at 5445 DTC Parkway, Suite 925, Greenwood Village, Colorado 80111, USA (“Ampio”). 

WHEREAS, Ethypharm and Valeant International (Barbados) SRL (formerly Biovail Laboratories International, SRL) (“Valeant”)
entered into that certain NDA Assignment and License Agreement dated as of February 6, 2009 (the “License Agreement”) under which Valeant was given rights from Ethypharm to use the Technology (as defined below) to develop and
commercialize the Product (as defined below) on a worldwide basis; 
 WHEREAS, pursuant to that certain Contract Assignment and
License Agreement, dated December 20, 2011, between Valeant and Ampio, Ampio was assigned all of Valeant’s rights under the License Agreement; 
 WHEREAS, pursuant to the terms of the License Agreement, Ampio has developed the Product and its related Regulatory Documentation (as defined below) and is in the process of registration of the Product in
different countries of the Territory (as defined below). 
 WHEREAS, pursuant to the terms of the License Agreement, Ampio has
engaged Ethypharm, who has accepted, as its exclusive manufacturer and supplier of the Product in the Territory; 
 NOW,
THEREFORE, in consideration of the foregoing premises and mutual covenants of the Parties hereinafter set forth, the parties agree as follows: 
 ARTICLE 1 
 DEFINITIONS 

“Affiliate” means, with respect to any Person, any other Person that (directly or indirectly) is controlled by,
controls, or is under common control with such Person. For purposes of this definition, the term “control” (including, with correlative meanings, the terms “controlled by” and “under common control with”) as used with
respect to a Person means direct or indirect beneficial or legal ownership of more than fifty percent (50%) of the voting interest in, or more than fifty percent (50%) of the equity of or the right to appoint more than fifty percent
(50%) of the directors or managers of the corporation or other business entity or the power to direct or cause the direction of the management and policies of such corporation or entity, whether pursuant to the ownership of voting securities,
by contract or otherwise. 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”.
A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

  

 “cGMP” shall mean the practices required with respect to the
manufacture of the Product by the provisions of EC Commission Directive 2003/94/CE together with the Guide to Good Manufacturing Practice published by the EC Commission in 1992 (ISBN 92-826-3180-X) and by the Food and Drug Administration in the
provisions of 21 C.F.R., parts 210 and 211. 
 “Commercial Manufacturing Site” means Ethypharm’s
manufacturing site at Châteauneuf en Thymerais, France, or any other manufacturing site to be agreed upon by both parties pursuant to the terms of this Agreement. 
 “Commercially Reasonable Efforts” means, with respect to the efforts to be expended by a party with respect to any objective, reasonable, diligent, good faith efforts to accomplish such
objective that such party would normally use to accomplish a similar objective under similar circumstances, it being understood and agreed that with respect to the research, development or commercialization of the Product, such efforts shall be
substantially equivalent to those efforts and resources commonly used by a party for a similar pharmaceutical product owned by it or to which it has rights, which product is at a similar stage in its development or product life and is of similar
market potential taking into account efficacy, safety, anticipated labeling, the competitiveness of alternative products in the marketplace, the patent and other proprietary position of the product, the likelihood of regulatory approval, commercial
value of the product, alternative products and other relevant factors. 
 “Confidential Information” means all
trade secrets, processes, formulae, data, know-how, improvements, inventions, chemical or biological materials, techniques, marketing plans, strategies, customer lists, or other information that has been created, discovered, or developed by a party
or its Affiliate, or has otherwise become known to a party or its Affiliate, or to which rights have been assigned to or by a party or its Affiliate (including, without limitation all information and materials of a party’s (or its
Affiliates’) customers and any other third party and their consultants), in each case that are disclosed by such party or its Affiliate to the other party, regardless of whether any of the foregoing is marked “confidential” or
“proprietary” or communicated to the other by the disclosing party in oral, written or graphic, or electronic form; provided, however, that Confidential Information shall not include any information: 

(A) that, at the time of its disclosure, is generally available within the industry; 

(B) that, after its disclosure in connection herewith, becomes generally available within the industry, through no act or
failure to act on the part of the receiving party or its Affiliates; 
 (C) that becomes available to the
recipient of such information from a third party that does not owe a duty of confidentiality to the disclosing party in relation to that Confidential Information; or 

(D) that the recipient of which can demonstrate was independently developed by or for such recipient without the aid,
application or use of the Confidential Information disclosed to the recipient by the disclosing party or its Affiliates in connection herewith. 

  

			
	CONFIDENTIAL	  	5 | Page

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”.
A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

  

 “Defect” means any flaw making the Product dangerous or unsuitable for
use or otherwise unsuitable for sale. 
 “Deficiency Notice” has the meaning set forth in
Section 4.7. 
 “Due Delivery Date” has the meaning set forth in Section 4.6.

 “Effective Date” means the date hereof. 

“EX Works” or :EXW” has the meaning provided in INCOTERM rules of the International Chamber of Commerce of 2010.

 “FDA” means the United States Food and Drug Administration or any successor government agency. 

“First Commercial Sale” means the first sale of the Product under this Agreement by Ampio, its Affiliates or Licenses in
arms’ length transaction to an unaffiliated Person. 
 “Forecast Report” has the meaning set forth in
Section 4.1. 
 “Ineligible Person” has the meaning set forth in Section 5.6.

 “Infringement Notice” has the meaning set forth in Section 11.1. 

“Intellectual Property” means all (i) patent applications, continuation applications, continuation in part
applications, divisional applications, any corresponding foreign patent applications to any of the foregoing, and any patents that may grant or may have been granted on any of the foregoing, including reissues, re-examinations and extensions;
(ii) rights in know-how, trade secrets, inventions (whether patentable or otherwise), data, processes, techniques, procedures, compositions, devices, methods, formulas, protocols and information, whether patentable or not;
(iii) copyrightable works, copyrights and applications, registrations and renewals; (iv) other intellectual proprietary rights; in each case, whether or not registered, applied for or granted; and (v) copies and tangible
memorializations of any one or more of the foregoing. 
 “Losses” has the meaning set forth in
Section 6.1. 
 “Notice of Observations” has the meaning set forth in Section 3.6.

 “Person” means a natural person, corporation, partnership, company or other entity. 

“Pain Field” means the prevention and/or treatment of pain in human beings. 

  

			
	CONFIDENTIAL	  	6 | Page

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”.
A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

  

 “Product” means an oral rapid dissolve or oral disintegrating tablet
formulation of TRAMADOL as the only active pharmaceutical ingredient in [***] dosage strengths for indication outside the Pain Field manufactured in accordance with the Specifications. 

“Quality Agreement” has the meaning set forth in Section 3.9. 

“Regulatory Approval” means the approvals or authorizations of relevant Regulatory Authorities, necessary for the
import, marketing and sale of the Product in the Territory. 
 “Regulatory Authority” means any competent
regulatory authority or other governmental body responsible for approving and authorizing the import, manufacture or marketing of Product in the Territory. 
 “Regulatory Documentation” means all submissions to the FDA or other Regulatory Authorities as applicable, including, without limitation, any clinical data, clinical studies, tests, and
biostudies, NDAs, as well as all correspondence with regulatory authorities, registrations and licenses, regulatory drug lists, advertising and promotion documents, adverse event files, complaint files, manufacturing records and inspection reports,
in each case related to or used in connection with the Product. 
 “Specifications” means all those
manufacturing, testing, packaging, labeling, storage and quality control specifications established for the Product by Ampio in compliance with the requirements of the cGMPs and other regulatory requirements, as set forth in Exhibit C hereto as may
be supplemented or amended from time to time by agreement of the parties, as further defined in the Quality Agreement. 

“Supply Interruption” has the meaning set forth in Section 4.6. 

“Supply Price” has the meaning set forth in Section 4.5 hereof. 

“Technology” means Ethypharm’s proprietary [***] technology, and all patents, patent applications, trademarks,
copyrights, proprietary know-how and all other related Intellectual Property rights owned by Ethypharm relating to the Product. 

“Term” has the meaning set forth in Section 9.1 hereof. 

“Territory” means all the different countries where the Product will be marketed by Ampio or its Licenses. 

“Third Party Manufacturer” has the meaning set forth in Section 2.2. 

  

			
	CONFIDENTIAL	  	7 | Page

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”.
A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

  

 ARTICLE 2 

APPOINTMENT OF MANUFACTURER 
 2.1 Requirements. During the Term, subject to Section 4.6 below, Ampio, itself or through its Affiliates or Licensees, shall purchase all of their requirements for Product exclusively from
Ethypharm, or its Third Party Manufacturer as applicable, and Ethypharm, and its Third Party Manufacturer as applicable, shall manufacture and supply to Ampio, its Affiliates and Licenses all of their requirements for Product. All Product
manufactured and supplied hereunder whether by Ethypharm or Third Party Manufacturer shall be performed in compliance with the Quality Agreement and Specifications including cGMP and all applicable laws, rules and regulations. 

2.2 Third Party Manufacturer. Ethypharm shall not subcontract its manufacturing and supply obligations hereunder to any third
party; provided, however, upon the prior written consent of Ampio, Ethypharm shall be entitled to contract with a third party for the purposes of such party’s producing part or all of the Product, and maintaining quality control with
respect to such Product, in lieu of and on behalf of Ethypharm (a “Third Party Manufacturer”) in which case Ethypharm shall remain liable to Ampio for all of its obligations, including but not limited to the performance of the Third
Party Manufacturer, herein, and Ampio shall either (at Ethypharm’s discretion) start purchasing the Product directly from the Third Party Manufacturer (according to the same terms and conditions as apply to the supply of Product by Ethypharm to
Ampio hereunder), or continue purchasing the Product through Ethypharm. Ethypharm shall give Ampio reasonable notice of any proposal to appoint a Third Party Manufacturer and shall satisfy all legal and regulatory requirements relating to any
variation of the Regularity Approval relating to such appointment at its own cost and shall procure for Ampio reasonable inspection and audit rights (which rights are no less favorable to Ampio than those it possesses hereunder with respect to
Ethypharm) in respect of the Third Party Manufacturer’s Manufacturing Site. Ethypharm shall warrant in writing to Ampio that the Third Party Manufacturer: (i) has and will maintain the requisite capacity to satisfy Ethypharm’s
production and delivery obligations, and to meet Ampio’s order requirements, hereunder with respect to the Product in accordance with the Specifications and the terms and conditions of this Agreement; (ii) complies and will comply with all
applicable laws and holds all applicable licensees and permits necessary for the manufacture of the Product in compliance with cGMP; (iii) has and will have the right to use all related intellectual property and Confidential Information of
Ethypharm necessary to manufacture the Product in accordance with the Specifications and the terms and conditions of this Agreement. 
 2.3 Joint Manufacturing Committee. On the Effective Date, the parties will establish a Joint Manufacturing Committee consisting of four members, two of whom shall be appointed by Ethypharm and two
of whom shall be appointed by Ampio. Initially, Ethypharm’s representatives to the Committee shall be Hafid Touam and Antoine Poncy, and Ampio’s representative shall be Amy Poshusta and one additional to be named. The Committee shall meet,
either in person or by teleconference, at least quarterly to discuss the following matters relating to the manufacture and supply of the Product: 
 1. coordinate forecasting, ordering and other supply-related logistics; 

  

			
	CONFIDENTIAL	  	8 | Page

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”.
A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

  

 2. discuss supply-related issues, including shortfalls and quality issues; 

3. discuss and coordinate manufacturing-related complaints, recalls and any other supply related issues; 

4. review and discuss proposals to engage, qualify and maintain Third Party Manufacturers and Additional Manufacturing Facilities; 

5. discuss the content and scope of any quality audit undertaken, or to be undertaken, relating to Third Party Manufacturers; 

6. review and agree on budgets for any additional technical assistance agreed to by the parties; 

7. discuss requirements for supply of Product and mechanisms to maintain supply, e.g., by increasing batch sizes and/or capacity or through
additional sources; 
 8. discuss technology and regulatory issues including tech transfer, changes in Specifications, API sourcing,
stability studies, inspections and audits; and 
 9. perform such other functions as may be appropriate with respect to the manufacture of
the Product. 
 All decisions of the Joint Manufacturing Committee will be made by unanimous vote. If the Committee cannot reach
agreement on any particular issue, the issue will be brought to the Chief Executive Officers of the parties, who shall have a period of 30 days to find an acceptable resolution to the issue. If the issue is not resolved during such 30 day period,
either party may bring the issue to a court of competent jurisdiction for resolution, in accordance with Section 11.1 below. 
 ARTICLE 3 
 REGULATORY AND QUALITY UNDERTAKINGS

 3.1 Regulatory. Ampio, as the holder of the Regulatory Approval, shall be responsible for obtaining,
maintaining and fulfilling all legal and regulatory requirements in the Territory at its own cost, with respect to the Product during the Term, as required by all applicable laws and regulations in the Territory. 

3.2 Import and Packaging. Ampio shall be responsible for the shipping, freight and handling of Product following its delivery to
Ampio at the Commercial Manufacturing Site and shall additionally be responsible for finished product packaging operations with respect to Product and shall ensure compliance with any and all laws and regulations in the Territory to the import and
export of the Product in the Territory. 
 3.3 Change in Specifications. In the event that a Regulatory Authority imposes
any change affecting the manufacture of the Product, the parties, acting through the Joint Manufacturing Committee, shall discuss in good faith with a view to reaching agreement on the 

  

			
	CONFIDENTIAL	  	9 | Page

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”.
A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

  

 
actions and timing required to effect such change, which shall be at the costs and expense of Ampio. All such changes required by any Regulatory Authorities or by Ampio shall be made at
Ampio’s costs and expenses. Any modifications to Specifications and /or the manufacturing instructions shall be implemented and validated in accordance with the terms of the Quality Agreement. 

3.4 Advertising, Promotional Materials, and Public Statements. Ampio shall be solely responsible for all sales, marketing and
advertising activities related to the Product in the Territory and shall ensure that all advertising and promotional materials comply with applicable laws, rules and regulations in the Territory. 

3.5 Product Complaints and Adverse Drug Experiences. Ampio shall, at its sole cost and expense, be responsible for handling all
customer Product complaints and all adverse event reporting, annual reporting, pharmacovigilance and other required, ongoing regulatory reporting activities normally and customarily associated with sales and marketing of pharmaceutical products in
the Territory, in each case, in accordance with applicable laws. 
 3.6 Facility Maintenance; Inspection; Reports. Each
party shall maintain and operate its respective facilities and implement such quality control procedures so as to meet the requirements of applicable FDA or any other relevant regulations and so as to be able to perform timely its obligations
hereunder. Each party shall (and shall cause its Third Party Manufacturers and packagers, if applicable, to) permit quality assurance representatives of the other party to inspect its facilities, including the Commercial Manufacturing Site, once per
calendar year upon reasonable written notice, during normal business hours and on a confidential basis; provided, that, if an inspecting party finds any non-compliance during any such inspection with respect to the Product, the party
subject to inspection shall (i) use Commercially Reasonable Efforts to promptly and diligently rectify such non-compliance and implement appropriate procedures with a view to avoiding such non-compliance and (ii) permit such additional
inspection(s) by the inspecting party as such inspecting party shall deem reasonably necessary to verify that such non-compliance has been rectified. Each party shall promptly provide the other party with a copy of any correspondences exchanged with
any Regulatory Authorities, together with the response and corrective action taken by the party with respect to the Product. 

3.7 Filing Requirements and Maintenance. Ampio shall promptly comply with all filing and reporting requirements with respect to
the Product, including general reporting requirements necessary to keep and maintain the Regulatory Documentation for the Regulatory Approval current with the Regulatory Authority and any applicable clinical study. Ampio shall be responsible for
conducting all stability studies at its own cost and expense that may be required for ongoing marketing and sale of the Product during the Term and such stability studies shall be conducted in compliance with the Regulatory Documentation, the
Regulatory Approval and other Regulatory Authorities requirements. 

  

			
	CONFIDENTIAL	  	10 | Page

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”.
A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

  

 3.8 Product Recall. 

                (a) Ampio or its
Affiliates, licensees or Licenses shall be responsible for handling the recall or seizure of any Product distributed by or on behalf of Ampio hereunder at its own costs and expense. Notwithstanding the foregoing, in the event Ampio decides to recall
or seize any Product distributed under this Agreement, and such recall or seizure is found to have been caused by a failure of Ethypharm to manufacture the Product in accordance with Specifications or cGMP, Ethypharm shall reimburse Ampio for all
external costs associated with such recall or seizure (including shipping, handling costs and credits to customers). Any decision to recall, withdraw or cease distribution of Product shall be made by Ampio only following consultation with Ethypharm,
taking such reasonable action as it considers to be appropriate under the circumstances to limit the risk to both parties and assure compliance by the parties with the requirements of applicable laws. For purposes of this Section 3.8,
“recall” means (i) any action by Ethypharm, Ampio or any Affiliate of either to recover title to or possession of any Product sold or shipped (including, but not limited to, market withdrawal) and/or (ii) any decision by
Ampio not to sell or ship any Products to third parties that would have been subject to recall if they had been sold or shipped, in each case taken in the good faith belief that such action was appropriate under the circumstances. For purposes of
this Section 3.8, “seizure” means any action by any governmental authority to detain or destroy any Product. 
                 (b) Following the First Commercial Sale, Ethypharm and Ampio shall keep the other fully informed in writing
of any notification or other information, whether received directly or indirectly, that might (i) affect the Regulatory Authority’s approval to market the Product under the Regulatory Approval or the safety or effectiveness of the Product,
(ii) result in liability issues or otherwise necessitate action on the part of either party, or (iii) result in the recall or seizure of the Product. Ampio will be responsible for assuring that such recall is closed-out with relevant
Regulatory Authority. 
 3.9 Quality Agreement. As promptly as practicable after the Effective Date, but in any event no
later than six months following the date of receipt by Ampio or its distributors or licensees of the first Regulatory Approval for the Product in the Territory, the parties will negotiate in good faith and execute a Quality Agreement (the
“Quality Agreement”) setting forth each party’s obligations for ensuring that the Product is manufactured and sold in compliance with cGMP and concerning the delimitation of pharmaceutical and quality responsibilities for the
manufacturing operations of the Product. This agreement shall contain administrative information with responsibilities, supply and manufacturing (premises, materials, batch numbering, shelf life and other information), customary provisions,
including change control, deviation, cGMP compliance, complaint handling and investigation, annual product review, QC testing (specification and method), documentations and inspections, batch release, product recalls, stability studies and other
quality related items in accordance with applicable regulation and guidelines in the Territory. 

  

			
	CONFIDENTIAL	  	11 | Page

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”.
A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

  

 ARTICLE 4 

FORECAST, ORDER, SUPPLY PRICE, SUPPLY INTERRUPTION 
 4.1 Forecast Reports. No later than six months following the date of receipt by Ampio or its distributors or licensees of the first Regulatory Approval for the Product in the Territory, Ampio shall
provide Ethypharm with a twelve (12) month forecast of its estimated requirements of the Product, which shall be updated quarterly during the Term to ensure that Ethypharm has at all times a twelve (12) month forecast for Ampio’s
estimated requirements of the Product (the “Forecast Report”). The Forecast Report shall be expressed in quantities of bulk tablet units of Product. Forecast Reports shall be provided to Ethypharm for information purposes only and
shall not constitute a firm commitment. 
 4.2 Product Orders. Ampio shall provide Ethypharm with binding and
non-cancellable orders of the Product four (4) months in advance, except for the first order to support the First Commercial Sale (the “Commercial Launch Supply”) which shall be placed six (6) months in advance. Ethypharm
shall accept all orders by written notice no later than ten (10) days following receipt of each relevant order and shall deliver such quantities of Product ordered unless the quantities ordered by Ampio vary by more than twenty-five percent
(25%) from the quantities indicated in the applicable Forecast Report. Ethypharm shall work with Ampio using Commercially Reasonable Efforts to deliver such quantities of Product that exceed more than twenty-five percent (25%) of the
estimated quantities of Product of the concerned Forecast Report. Ampio shall provide Ethypharm in each order with the exact quantity of Product, delivery date and the address to which the Product must be sent. These binding orders shall be
considered as firm offers and shall bind the Parties as soon as they are accepted in writing by Ethypharm. 
 4.3 Batch Sizes
of Product And Inventories.  
 (a) Each binding order placed by Ampio shall correspond to one full batch or multiple full
batches of the Product. A full batch size of Product is defined in Exhibit A of this Agreement. 
 (b) Any proposed change in
batch size shall be discussed with the Joint Manufacturing Committee before implementation. Ethypharm shall be responsible for implementing at its own discretion, any change in batch size during the Term taking into account the Forecast Reports.
Ampio shall be responsible for obtaining all regulatory approvals, required, to implement changes in full batch size required hereunder. 
 4.4 Inventories. Ampio shall at all times use reasonable efforts to keep adequate inventories of Product to meet the market demand in the Territory. These inventories shall be sufficient to cover
the estimated requirement for at least four (4) months. At Ampio’s request, such inventories shall be kept at Ethypharm’s facility on Ampio’s behalf. 

  

			
	CONFIDENTIAL	  	12 | Page

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”.
A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

  

 4.5 Supply Price of the Product. 

(a) All Product manufactured by Ethypharm or a Third Party Manufacturer, shall be supplied in bulk tablet form ready for
packaging and shall be delivered EX WORKS Ethypharm’s Commercial Manufacturing Site. Ethypharm Supply Price to Ampio is defined in Exhibit B of this Agreement. Ampio or its designated distributor or sublicensee shall be responsible for the
shipping, freight and handling of the Product from Ethypharm’s Commercial Manufacturing Site and finished dosage packaging. Ampio (a) shall pay Product invoices within thirty (30) days of date of invoice. Ethypharm shall supply the
Product in bulk tablet forms ready for packaging and shall deliver the Product to Ampio, EX WORKS (Ethypharm’s Commercial Manufacturing Site) (Incoterm 2010). The Supply Price as determined above includes the active ingredient, excipients,
testing and manufacturing workmanship according to Ethypharm’s usual standards and in compliance with cGMPs. 
 (b) [***] 
 (c) Ampio shall be responsible for all duties, tariffs,
import and similar charges other than sales and use taxes arising out of or related to the manufacture of the Product. None of these costs shall be subject to recoupment by Ampio from Ethypharm under this Agreement. 

(d) At any time during the Term of this Agreement, in the event that one of the Parties produces the written proof that an
unforeseeable event beyond the control of the Parties affects the economical conditions of the present Agreement so as to modify substantially the contractual balance of this Agreement for the sole benefit of one of the Party, the Parties agree to
revise the Supply Prices in good faith, taking into consideration the market of the Product in the Territory, in order to put back both Parties in a situation similar to the existing situation at the date of signature of the Agreement. Each Party
reserves the right to terminate this Agreement if the Parties are unable to reach an agreement within three (3) months starting from the first demand of conciliation by the most diligent Party. 

4.6 Supply Interruption. A “Supply Interruption” shall be deemed to have occurred if Ampio has not received
ordered Product for more than sixty (60) days past the scheduled and agreed upon due delivery date (“Due Delivery Date”) and Ampio holds no saleable stock of the Product after attempting to maintain at least four
(4) months of sealable stock through binding orders made pursuant to Section 4.3 (subject to Ethypharm’s delivery thereof), unless such Supply Interruption is caused by (a) a delay due to a shortage in supply of usable
active pharmaceutical ingredient or any other manufacturing material supplied by a third party through no fault of Ethypharm, (b) a material breach of this Agreement by Ampio for which Ethypharm has provided written notice thereof to Ampio or
(c) a Force Majeure Event. During a Supply Interruption, Ampio, shall be entitled to claim from Ethypharm a penalty of one per cent (1%) of the amount of the late deliveries value of Product from the third week of delay, per each week of
delay. The total amount of penalty to be paid by Ethypharm shall not exceed twenty per cent (20%) of the late deliveries value of Bulk Product not delivered. Such payment shall be made to Ampio within thirty (30) days date of Ampio’s
invoice. Notwithstanding the other provisions of 

  

			
	CONFIDENTIAL	  	13 | Page

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”.
A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

  

 
this Agreement, if a Supply Interruption lasts for more than three (3) months, Ampio shall be permitted, at its discretion, (i) to require Ethypharm to use a different supplier for the
Product, once Ampio has provided reasonable notice to Ethypharm of such requirement and/or (ii) to thereafter purchase some or all of its requirement for the Product from a third party of its choosing and Ethypharm shall grant all necessary
licenses and provide all necessary and reasonable cooperation to effect such transfer to the new manufacturing site, on conditions to be agreed in writing by the Parties and subject to appropriate confidentiality agreements being entered into by
such third party. 
 4.7 Deficiency Notice. Ampio shall have the right to reject any portion of any delivery of Product
that deviates from Specifications without invalidating any remainder of such delivery. Ampio shall inspect the Product upon receipt thereof and shall give Ethypharm written notice (a “Deficiency Notice”) of all claims for Product
that deviates from the Specifications within thirty (30) days after Ampio’s receipt thereof (or, in the case of any Defect not reasonably susceptible to discovery upon receipt by Ampio, within thirty (30) days after discovery thereof
by Ampio, up until the final release of the Product in its commercial packaging). Should Ampio fail to provide Ethypharm with a Deficiency Notice within the applicable period, then the delivery shall be deemed to have been accepted by Ampio upon the
expiration of such period. Notwithstanding the foregoing, if Ampio discovers that any Product materially deviates from Specifications after final release of the Product in its commercial packaging, such deviation was not reasonably susceptible to
discovery upon receipt of the Product from Ethypharm, and Ampio reasonably determines that such deviation was due to Ethypharm’s manufacturing, Ampio may reject the delivery of such Product within thirty (30) days after discovery thereof
by Ampio, up until the final expiration date of the Product. 
 4.8 Determination of Deficiency. Upon receipt of a
Deficiency Notice, Ethypharm shall have ten (10) business days to advise Ampio by notice in writing that it disagrees with the contents of such Deficiency Notice. Should Ethypharm fail to provide Ampio with a response to such Deficiency Notice
within the applicable period, then the delivery shall be deemed to have deviated from the Specifications upon the expiration of such period. If Ethypharm responds to such Deficiency Notice during such period and Ampio and Ethypharm fail to agree
within ten (10) business days of the date of Ethypharm’s response to Ampio as to whether any Product identified in the Deficiency Notice deviates from the Specifications, the parties shall mutually select an independent laboratory to
analyze the Product for compliance with the Specifications. Such analysis shall be binding on the parties, and Ampio may reject such Product if such analysis determines that the Product in question deviates from the Specifications. If such analysis
certifies that the Product does not deviate from the Specifications, Ampio shall be deemed to have accepted delivery of such Product on the fortieth (40th) day after delivery (or, in the case of any Defect not reasonably susceptible to
discovery upon receipt of the Product or Defect discovered after final release by Ampio of the Product in its commercial packaging pursuant to Section 4.7 above, on the fortieth (40th) day after discovery by Ampio, but in no event
after the expiration date of the Product). 

  

			
	CONFIDENTIAL	  	14 | Page

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”.
A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

  

 4.9 Rejection for Deficiency. If any delivery of Product is deemed or agreed upon
to deviate from the Specifications, at Ampio’s option, Ethypharm shall either (a) accept a return of such delivery, correct such delivery with replacement Product, if required, as soon as reasonably practicable and reimburse Ampio for its
shipping costs in connection with such delivery and such returns within thirty (30) days, or (b) shall reimburse Ampio for Ampio’s costs (including the purchase price of the Product and shipping costs with respect thereto within
thirty (30) days. 
 ARTICLE 5 
 WARRANTIES AND COVENANTS 
 5.1 Certain Representations and
Warranties of Ethypharm. Ethypharm represents and warrants to Ampio that as of the Effective Date (i) Ethypharm is duly organized and validly existing under the laws of the jurisdiction of its incorporation or organization;
(ii) Ethypharm has the full right, power and authority to enter into this Agreement and to perform the activities required to be performed by it in accordance with this Agreement; (iii) this Agreement is legally binding upon Ethypharm and
enforceable in accordance with its terms, and the execution, delivery and performance of this Agreement by Ethypharm does not conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by which it may be
bound, nor violate any material law or regulation or order of any court, governmental body or administrative or other agency having jurisdiction over it; (iv) there is no action, suit, proceeding or investigation pending or threatened, against
Ethypharm that questions the validity of this Agreement or the right of Ethypharm to enter into this Agreement or consummate the transactions contemplated hereby, nor does Ethypharm have knowledge that there is any basis for the foregoing;
(v) Ethypharm is not in violation of any law or regulation, nor is it aware of any violation of any law or regulation by any other person, which violation could reasonably be expected to adversely affect its performance of its obligations
hereunder and (vi) Ethypharm is the owner or licensee of its Intellectual Property and Technology pertaining to the Product, which is free and clear of any liens, charges and encumbrances. 

5.2 Certain Representations and Warranties of Ampio. Ampio represents and warrants to Ethypharm that as of the Effective Date
(i) Ampio is duly organized and validly existing under the laws of the jurisdiction of its incorporation or organization; (ii) Ampio has the full right, power and authority to enter into this Agreement, to perform the activities required
to be performed by it in accordance with this Agreement; (iii) this Agreement is legally binding upon Ampio and enforceable in accordance with its terms, and the execution, delivery, and performance of this Agreement by Ampio does not conflict
with any agreement, instrument or understanding, oral or written, to which it is a party or by which it may be bound, nor violate any material law or regulation of any court, governmental body or administrative or other agency having jurisdiction
over it; (iv) there is no action, suit, proceeding or investigation pending or threatened against Ampio that questions the validity of this Agreement or the right of Ampio to enter into this Agreement or consummate the transactions contemplated
hereby, nor does Ampio have knowledge that there is any basis for the foregoing; (v) Ampio is not in violation of any law or regulation, nor is it aware of any violation of any law or regulation by any other person, which violation could
reasonably be expected to adversely affect its performance of its obligations 

  

			
	CONFIDENTIAL	  	15 | Page

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”.
A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

  

 
hereunder; (vi) Prior to First Commercial Sale in any particular jurisdiction, Ampio or its distributor or licensee shall secure the right under the relevant Regulatory Approval to pursue
marketing and sale of the Product in such jurisdiction. 
 5.3 Certain Covenants of Ampio . Ampio covenants and agrees,
on behalf of itself and its Affiliates, that during the Term (i) any Intellectual Property of Ampio, including in particular trademarks of Ampio that are to be utilized by Ampio in connection with the labeling and packaging of the Product are
(or will be) the property of Ampio, may be lawfully used as directed by Ampio; (ii) it will not develop or perform any formulation or any developmental or other work or studies on or with respect to the Product for its own use or benefit or for
the use or benefit of any Person in the Territory, other than pursuant to the development and commercialization of the Product pursuant to the terms of the License Agreement. 
 5.4 Certain Covenants of Ethypharm . Ethypharm covenants and agrees on behalf of itself and its Affiliates and Third Party Manufacturer that it will not during the Term, directly or indirectly
alone, with or through a Third Party, sell, develop, manufacture or market a product containing tramadol anywhere in the world that is a dosage strength that is not a multiple of 25mg or not in the Pain Field, without the prior written consent of
Ampio. 
 5.5 Storage. Tablets of the Product under Ethypharm’s or Ampio’s control (as the case may be) prior
to distribution by Ampio in the Territory shall be stored by Ethypharm or Ampio in a compliant manner and handled in accordance with the Regulatory Documentation and applicable cGMP requirements. 

5.6 Representation and Warranties with Regard to Status . Ampio and Ethypharm each hereby represent and warrant to the other that,
subject to the receipt by Ampio or its distributors or sublicensees of relevant Regulatory Approvals, neither it, their Affiliates, nor in the case of Ethypharm the Third Party Manufacturer nor any of the officers, directors or employees of the
foregoing is prohibited by any law, rule or regulation or by any order, directive or policy from selling the Product or other pharmaceutical products within the Territory and that neither it nor any of its officers, directors, employees or
Affiliates or Third Party Manufacturer is a Person that is listed by a United States federal agency as debarred, suspended or otherwise ineligible for federal programs in the United States, its territories and protectorates (an “Ineligible
Person”) or proposed for such debarment or suspension. 
 5.7 Compliance with Specifications and cGMP .
Ethypharm covenants and agrees that the Product, when delivered to Ampio, will be manufactured, controlled and supplied in accordance with the Specifications and with cGMP; the Product will meet Ethypharm’s quality assurance standards; Product
ingredients and contents will conform with the list and Specifications for ingredients set forth in the Regulatory Approval. Ethypharm will sell the Product to Ampio free of all liens and encumbrances. Ethypharm and Ampio shall execute the Quality
Agreement in accordance with the terms hereof. 

  

			
	CONFIDENTIAL	  	16 | Page

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”.
A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

  

 5.8 Limitation of Warranty. EITHER PARTY GIVES NO OTHER WARRANTY UNDER THIS
AGREEMENT, EXPRESS OR IMPLIED, INCLUDING THE WARRANTIES OF NON-INFRINGEMENT, OF MERCHANTABILITY OR OF FITNESS FOR A PARTICULAR PURPOSE. 
 ARTICLE 6 
 INDEMNIFICATION AND LIMITATION OF LIABILITY

 6.1 Ethypharm’s Indemnification Obligations . Ethypharm shall indemnify and hold Ampio and its Affiliates
and their respective officers, directors, stockholders, employees and agents harmless from and against, and pay or reimburse, any claim, action, suit, proceeding, loss, liability, damage or expense (including reasonable attorneys’ fees)
(collectively, “Losses”) related to claims asserted by any third party, directly or indirectly, as a result of Ethypharm’s or its Affiliates’ or Third Party Manufacturer’s failure to manufacture the Product in
accordance with the Specifications or cGMP or of Ethypharm’s breach of any of its representations, warranties, covenants hereunder; provided, however, that Ethypharm shall not be required to indemnify Ampio with respect to any
such Losses to the extent such Losses arise from or relate to Ampio’s or its Affiliates’ negligent acts or omissions, willful wrongful acts or Ampio’s breach of its representations, warranties, covenants or other obligations
hereunder. 
 6.2 Ampio’s Indemnification Obligations . Ampio shall indemnify and hold Ethypharm and its Affiliates
and their respective officers, directors, stockholders, employees and agents harmless from and against, and pay or reimburse, any Losses related to claims asserted by any third party, directly or indirectly, as a result of: (a) Ampio’s or
its Affiliates’ negligent acts or omissions, willful wrongful acts or breach of any of its representations, warranties, covenants or other obligations hereunder; (b) liabilities, expenses or damages arising from the actions of Ampio to
promote, market, commercialize, distribute and sell the Product in the Territory; and (d) liabilities, expenses or damages arising from the actions of Ampio’s distributors, Affiliates and Licenses or brought by such distributors,
Affiliates or Licenses; provided, however, that Ampio shall not be required to indemnify Ethypharm with respect to any such Losses to the extent such Losses arise from or relate to Ethypharm’s, its Affiliates’ or
subcontractors’ negligent acts or omissions, willful wrongful acts or Ethypharm’s breach of its representations, warranties, covenants or other obligations hereunder. 

6.3 Indemnification Procedures . A party that intends to claim indemnification under this Article 6 (the
“indemnitee”) with respect to any third-party action, claim or liability shall notify the other party (the “indemnitor”) promptly in writing of any action, claim or liability in respect of which the indemnitee
believes it is entitled to claim indemnification; provided, that the failure to give timely notice to the indemnitor shall not release the indemnitor from any liability to the indemnitee except to the extent the indemnitor is
materially prejudiced thereby. The indemnitor shall have the right, by written notice to the indemnitee, to assume the defense of any such action or claim, within the fifteen (15) day period after the indemnitor’s receipt of written notice
of any action or claim, with counsel of the indemnitor’s choice and at the sole cost of the indemnitor. If the indemnitor so assumes such defense, the indemnitee may 

  

			
	CONFIDENTIAL	  	17 | Page

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”.
A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

  

 
participate therein through counsel of its choice, but at the sole cost of the indemnitee; provided, however, if the defendants in any such action include both the party seeking
indemnification and the indemnifying party, and the party seeking indemnification shall reasonably conclude that there may be legal defenses available to it which are different from or additional to, or inconsistent with, those available to the
indemnifying party, the party seeking indemnification shall have the right to select separate counsel to participate in the defense of such action on behalf of such party seeking indemnification, at the indemnifying party’s expense. If the
indemnitor fails to assume such defense and/or to diligently prosecute the same, the indemnitee may assume such defense at the indemnitor’s sole expense. The party not assuming the defense of any such claim shall render all reasonable
assistance to the party assuming such defense, and all reasonable out-of-pocket costs of such assistance shall be for the account of the indemnitor. No such claim shall be settled other than by the party defending the same, and then only with the
prior written consent of the other party, which consent shall not be unreasonably withheld, conditioned or delayed; provided, however, that the indemnitee shall have (i) no obligation to consent to any settlement of any such
action or claim that (a) imposes on the indemnitee any monetary or other liability or obligation that is not assumed and agreed to be performed in full by the indemnitor or (b) adversely affects the indemnitee’s rights hereunder or
damages its reputation or business, and (ii) no right to withhold its consent to any settlement of any such action or claim if the settlement involves only the payment of money by the indemnitor or its insurer without admission of liability by
the indemnitee and the indemnitor or its insurer irrevocably agrees in writing to make such payment. If the parties are unable to agree as to the application of Sections 6.1 and 6.2 to any claim, pending resolution of the dispute in
accordance with Section 11.1, the parties may conduct separate defenses of such claims, with each party retaining the right to claim indemnification from the other party in accordance with Sections 6.1 and 6.2 upon
resolution of the underlying action. 
 6.4 Limitation of Liability . NEITHER PARTY SHALL BE LIABLE WITH RESPECT TO ANY
CLAIM RELATED TO THIS AGREEMENT FOR ANY SPECIAL, INCIDENTAL OR INDIRECT DAMAGES, INCLUDING ANY LOSS OF INCOME, LOSS OF PROFITS, COSTS OF SUBSTITUTION, COSTS OF COVER OR INCREASED CAPITAL COSTS, REGARDLESS OF THE FORM OR NATURE OF ACTION, WHETHER IN
CONTRACT, BREACH OF WARRANTY, STRICT LIABILITY, EQUITY, INDEMNITY, NEGLIGENCE, INTENTIONAL CONDUCT, TORT OR OTHERWISE, EVEN IF SUCH DAMAGES WERE FORESEEABLE OR IF THE PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. 

ARTICLE 7 
 INSURANCE 
 Each of Ampio and Ethypharm shall (and shall cause their
respective Affiliates and Sub-licensees, as required, to), upon the Effective Date, carry or be subject to coverage (as a named insured) under product liability insurance in an amount of not less than [***] combined single limit, which insurance
shall be written on a “claims-made” policy basis with an insurance carrier rated at least A- by Bests Rating Service or a comparable rating by a comparable rating service. 

  

			
	CONFIDENTIAL	  	18 | Page

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”.
A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

  

 
Each party shall provide the other party with evidence of coverage contemplated hereby, in the form of certificates of insurance, as reasonably requested in writing. Each party shall provide
written notice to the other party fifteen (15) days prior to any material change, cancellation or non-renewal of the policy. 
 ARTICLE 8 
 CONFIDENTIALITY 

8.1 Treatment of Confidential Information . Except as required by applicable laws and regulations or as otherwise provided in this
Article 8, during the Term, and for ten (10) years thereafter, each party shall hold in confidence, and may not disclose, in whole or in part, to a third party (except as specifically set forth herein or with the express prior written
consent of the other party) any and all Confidential Information of the other party and its Affiliates. During the Term, the parties may not use any Confidential Information of the other party and its Affiliates for purposes other than those
permitted by this Agreement and the License Agreement. 
 8.2 Limits on Disclosure . Without limiting the generality of
the foregoing, each party may, with the exercise of reasonable discretion, (i) disclose Confidential Information to those employees or agents who need to receive the Confidential Information in order to further the activities contemplated by
this Agreement; and (ii) make disclosures of such portions of Confidential Information to third-party consultants, attorneys, contractors, advisors, Affiliates and governmental authorities where, in such party’s judgment, such disclosure
is beneficial to the development, approval or marketing of the Product pursuant to this Agreement; provided, that such party shall take reasonable precautions to safeguard the Confidential Information, including by obtaining appropriate commitments
and enforceable confidentiality agreements having provisions no less stringent than those contained herein. 

(a) Each party understands and agrees that the wrongful disclosure of Confidential Information may result in serious and
irreparable damage to the other party, that the remedy at law for any breach of this covenant may be inadequate, and that the party seeking redress hereunder shall be entitled to injunctive relief, without prejudice to any other rights and remedies
to which such party may be entitled. 
 (b) Except as otherwise set forth in this Agreement, upon the termination
or expiration of this Agreement and at the written request of the disclosing party, the receiving party shall return all Confidential Information of the disclosing party (including all copies, excerpts and summaries thereof contained on any media)
or destroy such Confidential Information at the option of the receiving party; provided, that the receiving party may retain one copy of all Confidential Information of the disclosing party for its legal records. 

  

			
	CONFIDENTIAL	  	19 | Page

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”.
A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

  

 ARTICLE 9 

TERM AND TERMINATION 
 9.1 Term. This Agreement shall be effective immediately upon the Effective Date and shall remain into effect for a period of ten (10) years from the Effective Date (the
“Term”). Upon the expiry of the Term, this Agreement will be automatically renewed for one or more additional three (3) year periods, unless terminated by any of the Parties six (6) months prior to the end of the initial
period, or any of the renewed period, by proper notice. 
 9.2 Termination for Breach. If either party commits a material
breach or default in the performance or observance of any of its obligations under this Agreement, other than nonpayment of a monetary obligation, and such breach or default continues for a period of sixty (60) days after delivery by the other
party of written notice reasonably detailing such breach or default, or, if the non-performing party shall promptly, within such sixty (60) days, proceed with all due diligence to cure such failure, and such failure is not cured within such
longer period (not to exceed one hundred eighty (180) additional days) as shall be reasonably necessary for such party to cure the same with all due diligence, then the non-breaching or non-defaulting party shall have the right to terminate
this Agreement, with immediate effect, by giving written notice to the breaching or defaulting party. Nonpayment of a monetary obligation is deemed a material breach hereunder and the non-breaching party may terminate this Agreement if such breach
continues for a period of thirty (30) days after delivery to the breaching party of written notice of non-payment, with termination effective on the date provided for in that. If either Ethypharm, its Third Party Manufacturer or Ampio becomes
an Ineligible Person, such status shall constitute a material breach hereunder, and the non-breaching party may terminate this Agreement if such breach continues for a period of thirty (30) days after delivery to the breaching party of written
notice of termination, with termination effective on the date provided for in that notice. 
 9.3 Termination for
Bankruptcy. To the extent permitted by law, this Agreement shall automatically terminate upon the initiation of any proceeding in bankruptcy, reorganization or arrangement for the appointment of a receiver or trustee to take possession of the
assets of either party or a similar proceeding under law for the release of creditors by or against either party, or if either party makes a general assignment for the benefit of its creditors. 

9.4 Withdrawal of Regulatory Approval and NDA. This Agreement may be terminated with respect to relevant countries in the
Territory by either party in the event that a Regulatory Authority in the Territory withdraws the concerned Regulatory Approval for future marketing of Product in the concerned country of the Territory. 

9.5 No Waiver of Termination Rights. The right of either party to terminate this Agreement, as provided in this Article 9,
shall not be affected in any way by its waiver of, or failure to take action with respect to, any previous default. 

  

			
	CONFIDENTIAL	  	20 | Page

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”.
A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

  

 ARTICLE 10 

FORCE MAJEURE 
 10.1 Effects of Force Majeure. A party hereto shall be excused and shall not be held liable or responsible for failure or delay in fulfilling or performing any of its obligations under this
Agreement (other than the payment of money) if such failure or delay is caused by acts of God, acts of the public enemy, fire, explosion, flood, epidemic or other natural physical disaster, drought, war, terrorists, riot, unavailability of raw
material, sabotage, embargo, strikes or other labor disputes, intervention of governmental authority, impossibility of the use of railways, shipping, aircraft, motor transport or other means of public or private transport, failure or suspension of
utilities, and political interference with the normal operation of either party or by any other event or circumstance of like or different character to the foregoing beyond the reasonable control and without the fault or negligence of the affected
party (a “Force Majeure Event”). Such excuse shall continue as long as the Force Majeure Event continues. Upon cessation of such Force Majeure Event, such party shall promptly resume performance hereunder. 

10.2 Notice of Force Majeure. Each party agrees to give the other party prompt written notice of the occurrence of any Force
Majeure Event, the nature thereof and the extent to which the affected party will be unable to perform its obligations hereunder. Each party further agrees to use reasonable efforts to correct or otherwise address the Force Majeure Event as soon as
practicable and to give the other parties prompt written notice when it is again fully able to perform such obligations. 

ARTICLE 11 
 Miscellaneous 
 11.1 Dispute Resolution. Ethypharm and Ampio
agree to irrevocably submit to the exclusive jurisdiction of (i) the Supreme Court of the State of New York, New York County, U.S.A., or (ii) the United States District Court for the Southern District of New York U.S.A., for the purposes
of any suit, action or other proceeding arising out of this Agreement or any transaction contemplated hereby. Each Party agrees to commence any such action, suit or proceeding either in the United States District Court for the Southern District of
New York, U.S.A. or, if such suit, action or other proceeding may not be brought in such court for jurisdictional reasons, in the Supreme Court of the State of New York, New York County, U.S.A. 

EACH PARTY HERETO WAIVES, TO THE EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT TO ANY LITIGATION DIRECTLY OR
INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT, AND EACH PARTY HERETO (i) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN
THE EVENT OF LITIGATION, SEEK TO ENFORCE THAT FOREGOING WAIVER, AND (ii) ACKNOWLEDGES THAT IT AND THE OTHER PARTY HERETO HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS
PARAGRAPH. 

  

			
	CONFIDENTIAL	  	21 | Page

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”.
A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

  

 11.2. Independent Contractors. The relationship between Ethypharm, on the one
hand, and Ampio, on the other hand, is that of independent contractors and nothing herein shall be deemed to constitute or create the relationship of partners, joint venturers nor of principal and agent between Ethypharm on the one hand and Ampio on
the other hand. Neither party shall have any express or implied right or authority to assume or create any obligations on behalf of or in the name of the other party or to bind the other party to any contract, agreement or undertaking with any third
party. 
 11.3. Assignment. This Agreement may be assigned and/or delegated by either party to an Affiliate of such party
or in connection with any sale, merger or other business combination involving all or substantially all of such party’s assets or capital stock or of the assets to which this Agreement relates. Except as otherwise provided in this Agreement,
neither this Agreement nor any other rights or obligations hereunder shall be assigned, transferred or delegated by either party without the prior written consent of the other party, not to be unreasonably withheld, conditioned or delayed. Any
permitted assignee shall, upon the request of the other party hereto, expressly acknowledge, by written agreement, its assumption of all obligations and liabilities under this Agreement. Any attempted assignment in violation of the foregoing shall
be null and void. This Agreement shall inure to the benefit of each party’s permitted successors and assigns. 
 11.4.
Governing Law. This contract shall be governed by, and construed in accordance with, the laws of the State of New York without reference to that state’s conflicts of laws rules. The parties expressly reject the application of the United
Nations Convention on Contracts for the International Sale of Goods and all implementing legislation thereunder. 
 11.5. No
Implied Waiver. No failure or delay on the part of either party hereto to exercise any right, power or privilege hereunder or under any instrument executed pursuant hereto shall, in itself, operate as a waiver; nor shall any single or partial
exercise of any right, power or privilege preclude any other or further exercise thereof or the exercise of any other right, power or privilege. 
 11.6. Notice. All notices required to be given hereunder shall be in writing and shall be given by personal delivery, via facsimile transmission followed by U.S. mail, by a nationally recognized
overnight carrier or by registered or certified mail, postage prepaid with return receipt requested. Notices shall be addressed to the parties as follows: 
 If to Ethypharm: 
 Ethypharm S.A. 

194 Bureaux de la Colline 
 F92213 Saint-Cloud 

  

			
	CONFIDENTIAL	  	22 | Page

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”.
A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

  

 France 
 Attn: Hugues LECAT—Chairman of the Board—CEO 
 Facsimile No.: +33 1 41 12
17 30 
 With a copy (which shall not constitute notice) to: 

Ethypharm USA Corp. 
 1500 Market Street, 12th Floor, East Tower 
 Philadelphia, PA 19102 

Attn: Hafid Touam-CEO 
 Facsimile No.: (610) 994-2302 
 If to Ampio: 

Ampio Pharmaceuticals, Inc. 
 The Quadrant 
 5445 DTC Parkway, Suite 925 

Greenwood Village, CO 80111 
 U.S.A. 
 Attn: Michael Macaluso—Chairman of the Board and CEO 

Facsimile (720) 437-6501 
 With a copy (which shall not constitute notice) to: 
 Goodwin Procter LLP

 Exchange Place 
 Boston, MA 02109 
 Attention: Larry Wittenberg 

Facsimile: 617-523-1231 

Notices delivered personally shall be deemed communicated as of actual receipt; notices sent via facsimile transmission shall be deemed communicated as
of receipt by the sender of written confirmation of transmission thereof; notices sent via overnight courier shall be deemed received as of one business day following sending; and notices mailed shall be deemed communicated as of three
(3) business days after proper mailing. A party may change his or its address by written notice sent in accordance with this Section 12.6. 
 11.7. Amendments. Any amendment or modification of this Agreement shall be valid only if made in writing and signed by both parties hereto. 

11.8. Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original and both of which
shall constitute a single document. A facsimile signature of an authorized signatory of either party shall be valid and binding and constitute due execution and delivery of this Agreement by such party. 

  

			
	CONFIDENTIAL	  	23 | Page

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”.
A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

  

 11.9. Interpretation. The Section headings contained in this Agreement are for
the convenience of reference only and shall not affect the meaning or interpretation of this Agreement. As used in this Agreement, any reference to the masculine, feminine or neuter gender shall include all genders, the plural shall include the
singular, and the singular shall include the plural. Unless the context otherwise requires, the term “party” when used herein means a party hereto. References herein to a party or other Person include its respective successors and
permitted assigns. The words “includes” and “including” when used herein shall be deemed to be followed by the phrase “without limitation” unless such phrase otherwise appears. Unless the context
otherwise requires, references herein to Articles, Sections, Exhibits and Schedules shall be deemed references to Articles and Sections of, and Exhibits and Schedules to, this Agreement. Unless the context otherwise requires, the words
“hereof,” “hereby,” “hereunder” and “herein” and words of similar meaning when used in this Agreement refer to this Agreement in its entirety and not to any particular Section or
provision hereof. All monetary amounts in this Agreement are expressed and shall be paid in U.S. dollars. With regard to each and every term and condition of this Agreement, the parties understand and agree that the same has or have been mutually
negotiated, prepared and drafted, and that, if, at any time, the parties desire or are required to interpret or construe any such term or condition or any agreement or instrument subject thereto, no consideration shall be given to the issue of which
party actually prepared, drafted or requested any term or condition of this Agreement. 
 11.10. Entire Agreement. This
Agreement and the License Agreement constitutes the entire understanding between the parties with respect to the subject matter hereof and supersedes all prior contracts, agreements and understandings related to the same subject matter between the
parties. In particular, in case of inconstancies between the terms of the License Agreement and the terms of this Agreement with respect to the manufacture and supply of the Product, the terms of this Agreement shall prevail. The parties intend this
Agreement to be a complete statement of the terms of their understanding. 
 11.11. Benefit; Binding Effect. This
Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors and permitted assigns. 
 11.12. Survival. Notwithstanding anything to the contrary contained in this Agreement, the provisions of Article 3 (to the extent of post-termination complaints and reporting obligations)
and Articles 1, 5, 6, 7, 8 11and 12 shall survive, in accordance with their respective terms, any termination or expiration of this Agreement. 

11.13. Further Assurances. The parties agree that they shall take all appropriate actions, including the execution or filing of
any documents or instruments, that may be reasonably necessary or advisable to carry out the intent and accomplish the purposes of any of the provisions hereof. 
 11.14. Severability. In the event that any provision of this Agreement shall be held invalid or unenforceable for any reason by a court of competent jurisdiction, such provision or part thereof
shall be considered separate from the remaining provisions of this Agreement, which shall remain in full force and effect. Such invalid or unenforceable provision shall be deemed revised to effect, to the fullest extent permitted by applicable law,
the intent of the parties as set forth herein. 

  

			
	CONFIDENTIAL	  	24 | Page

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”.
A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

  

 11.15. Use of Names; Publicity. Neither party will use the name of the other
party or issue any press release or other publicity relating to this Agreement in any form without the written permission of the other, except as may be required by applicable law (including securities exchange rules) or as otherwise contemplated
hereunder. Neither party will unreasonably withhold its written permission if the other party desires to issue such a press release or other publicity with respect to this Agreement. 

  

			
	CONFIDENTIAL	  	25 | Page

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”.
A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

  

 IN WITNESS WHEREOF, the parties have caused this Agreement to be executed as of
the Effective Date. 
 Date: 
  

			
	ETHYPHARM S.A.
		
	By:	 	/s/ Hugues LECAT
	Name:	 	Hugues LECAT
	Title:	 	CEO—Chairman of Management Board

  

			
	AMPIO PHARMACEUTICALS, INC.
		
	By:	 	/s/ Michael Macaluso
	Name:	 	Michael Macaluso
	Title:	 	Chairman of the Board and CEO

  

			
	CONFIDENTIAL	  	26 | Page

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”.
A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

  

 EXHIBIT A 
 BATCH SIZE DEFINITION 
 A full batch size of Product represents [***]. 

  

			
	CONFIDENTIAL	  	27 | Page

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”.
A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

  

 EXHIBIT B 
 SUPPLY PRICES 
 Ethypharm Supply prices of Product expressed EX WORKS (Ethypharm Commercial
Manufacturing Site) taxes excluded, in bulk tablets, to Ampio shall be: 
 [***] 
 [***] 
 The Supply Price as determined above includes the supply of excipients and active
drug, the analysis of active drug and excipient, the manufacturing operations according to the standards of ETHYPHARM and the delivery in bulk packaging Ex Works as indicated. 

  

			
	CONFIDENTIAL	  	28 | Page

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”.
A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

  

 EXHIBIT C 
 PRODUCT SPECIFICATIONS 

  

			
	CONFIDENTIAL	  	29 | PageEX-10.44

 Exhibit 10.44 
 

 
 To: Sheryl Roland 
 From: Kory Vossoughi 
 Effective Date: July 30, 2012 

 

	Re:	Amended and Restated Change in Control Agreement 

 The Active Network, Inc. (the “Company”) considers it essential to the best interests of its stockholders to foster the continuous employment of the Company’s key management
personnel. In this regard, the Company’s Board of Directors (the “Board”) recognizes that the possibility of a change in control of the Company may exist in the future and the uncertainty and questions that it may raise
among management could result in the departure or distraction of management personnel to the detriment of the Company and its shareholders. 
 The Board has decided to reinforce and encourage the continued attention and dedication of members of the Company’s management, including yourself, to their assigned duties without the distraction
arising from the possibility of a change in control of the Company. 
 In order to induce you to remain in its employ, the
Company hereby agrees that after this letter agreement (this “Agreement”) has been fully executed, you shall receive the benefits set forth in this Agreement in the event that your employment with the Company is terminated
under the circumstances described below subsequent to a Change in Control (as defined below). 
 1. Change in Control.
You shall receive no benefits under this Agreement unless there has been a Change in Control. For purposes of this Agreement, a “Change in Control” shall mean and include each of the following: 

(a) A transaction or series of transactions (other than an offering of the Company’s common stock to the general public through a
registration statement filed with the Securities and Exchange Commission) whereby any “person” or related “group” of “persons” (as such terms are used in Sections 13(d) and 14(d)(2) of the Securities Exchange Act of
1934, as amended (the “Exchange Act”)) (other than the Company, any of its subsidiaries, an employee benefit plan maintained by the Company or any of its subsidiaries or a “person” that, prior to such transaction,
directly or indirectly controls, is controlled by, or is under common control with, the Company) directly or indirectly acquires beneficial ownership (within the meaning of Rule 13d-3 under the Exchange Act) of securities of the Company possessing
more than fifty percent (50%) of the total combined voting power of the Company’s securities outstanding immediately after such acquisition; or 
 (b) The consummation by the Company (whether directly involving the Company or indirectly involving the Company through one or more intermediaries) of (i) a merger, consolidation, reorganization, or
business combination or (ii) a sale or other disposition of all or substantially all of the Company’s assets or (iii) the acquisition of assets or stock of another entity, in each case other than a transaction: 

(A) Which results in the Company’s voting securities outstanding immediately before the transaction continuing to
represent (either by remaining 

 
outstanding or by being converted into voting securities of the Company or the person that, as a result of the transaction, controls, directly or indirectly, the Company or owns, directly or
indirectly, all or substantially all of the Company’s assets or otherwise succeeds to the business of the Company (the Company or such person, the “Successor Entity”)) directly or indirectly, at least a majority of the
combined voting power of the Successor Entity’s outstanding voting securities immediately after the transaction, and 
 (B) After which no person or group beneficially owns voting securities representing fifty percent (50%) or more of the combined voting power of the Successor Entity; provided, however, that no
person or group will be treated for purposes of this definition as beneficially owning fifty percent (50%) or more of the combined voting power of the Successor Entity solely as a result of the voting power held in the Company prior to the
consummation of the transaction; or 
 (c) The Company’s stockholders approve a liquidation or dissolution of the Company.

 The Board will have full and final authority, which will be exercised in its discretion, to determine conclusively whether a
Change in Control of the Company has occurred pursuant to the above definition, and the date of the occurrence of such Change in Control and any incidental matters relating thereto. Notwithstanding the foregoing, the following events shall not
constitute a “Change in Control”: (i) a mere reincorporation of the Company; (ii) a transaction undertaken for the sole purpose of creating a holding company that will be owned in substantially the same proportion
by the persons who held the Company’s securities immediately before such transaction; (iii) the Company’s (or any successor entity’s) initial public offering of its equity securities; or (iv) a transaction effected primarily
for the purpose of financing the Company with cash (as determined by the Board in its discretion and without regard to whether such transaction is effectuated by a merger, equity financing or otherwise). 

2. Severance Benefits 
 (a) Benefits Upon Termination. If a Change in Control occurs and your employment is terminated voluntarily by you for Good Reason (as defined below) within the twelve (12) month period
immediately following the date of such Change in Control, or if your employment is terminated by the Company other than for Cause (as defined below) at any time, then, in lieu of any severance benefits to which you may otherwise be entitled under
any severance plan or program of the Company, you shall be entitled to the benefits provided below: 
 (i) the Company shall,
on the date of termination, pay to you your full earned but unpaid base salary, when due, through the date of termination at the rate in effect at the time notice of termination is given, plus all other amounts to which you are entitled under any
compensation plan or practice of the Company at the time such payments are due; 
 (ii) subject to your compliance with
Section 2(b) and Section 3, you shall be entitled to receive severance pay equal to your monthly Base Salary (as defined below) for a period of twelve (12) months, payable in a lump sum within fifteen (15) days of the Release
Effective Date (as defined below). Your “Base Salary” will be the rate of your base salary from the Company as in effect on the date of your discharge from employment with the Company (or, if greater, the rate of your base
salary from the Company immediately prior to the Change in Control); 

 (iii) subject to your compliance with Section 2(b) and Section 3, if you elect
continued coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”), the Company will pay the portion of the premiums of your group health insurance coverage, including coverage for your
eligible dependents, that exceeds the contributions required by you immediately prior to your date of termination for a period of twelve (12) months following your date of termination; provided, further, that the Company will pay
premiums for your eligible dependents only for coverage for which those eligible dependents were enrolled immediately prior to the date of termination of your employment. No premium payments will be made following the effective date of your
eligibility for coverage by a health insurance plan of a subsequent employer. For the balance of the period that you are entitled to coverage under federal COBRA law, if any, you will be entitled to maintain such coverage at your own expense;

 (iv) subject to your compliance with Section 2(b) and Section 3, with respect to the termination of
your employment by the Company other than for Cause and other than within the twelve (12) month period immediately following the date of a Change in Control, the vesting and/or exercisability of such number of Stock Awards that would vest over
the twelve (12) month period following your date of termination had you remained continuously employed by the Company through such period shall be automatically accelerated as of your date of termination. For purposes of this Section 2(a),
“Stock Awards” means all stock options, restricted stock and such other awards granted pursuant to the Company’s stock option and equity incentive award plans or agreements and any shares of stock issued upon exercise
thereof; 
 (v) subject to your compliance with Section 2(b) and Section 3, with respect to the termination of your
employment by the Company other than for Cause or the termination of your employment by you for “Good Reason” within the twelve (12) month period immediately following the date of a Change in Control, one hundred percent
(100%) of the unvested Stock Awards shall be automatically accelerated as of your date of termination; 
 (vi) you shall
be entitled to receive an amount equal to your target annual bonus for the fiscal year during which the termination occurs, with such bonus determined assuming that all of the performance objectives for such fiscal year have been attained, prorated
based on the number of days during such fiscal year you were employed by the Company; and(vii) subject to certain limited exceptions, your Stock Awards shall remain exercisable for a period of one year following the termination date. 

(b) Release. Prior to the payment of any benefits under this Agreement, you will be required to execute a release (the
“Release”) in the form attached hereto and incorporated herein as Appendix A or Appendix B, as applicable. Such Release will specifically relate to all of your rights and claims in existence at the
time of the execution thereof and will confirm your obligations under the Company’s standard form of employee confidentiality and inventions agreement. As specified in the applicable Release, you will have a certain number of calendar days to
consider whether to execute such Release, and you may revoke such Release within seven (7) calendar days after execution, if applicable. You must execute the Release and not revoke the Release in order to be entitled to benefits under this
Agreement. Your “Release Effective Date” will be the later of (i) the day upon which you execute the Release or (ii) the day upon which the seven (7) day revocation period applicable to such Release, if any,
expires without a revocation of such Release by you. Your Release Effective Date must be within fifty-five (55) days following the date of your termination of employment. If your Release Effective Date does not occur within fifty-five
(55) days of your termination of employment, you will not be entitled to benefits under this Agreement. 

 (c) No Mitigation. Subject to Section 2(a)(iii) above, you shall not be required
to mitigate the amount of any payment provided for in this Section 2 by seeking other employment or otherwise, nor shall the amount of any payment or benefit provided for in this Section 2 be reduced by any compensation earned by you as
the result of employment by another employer or self-employment, by retirement benefits, by offset against any amounts (other than loans or advances to you by the Company) claimed to be owed by you to the Company, or otherwise. 

(d) Definition of Cause. For purposes of this Agreement, “Cause” shall mean (i) your gross
negligence, breach of fiduciary duty involving personal profit, personal dishonesty, recklessness or willful misconduct with respect to your obligations or otherwise relating to the business of the Company; (ii) the material breach of any
agreement between you and the Company, including Company policies and practices; (iii) your conviction or entry of a plea of nolo contendere for fraud or embezzlement, or any felony or crime of moral turpitude; or (iv) your willful neglect
of duties or failure to satisfactorily perform stated duties, in each case as determined in good faith by the Board. 
 (e)
Definition of Good Reason. For purposes of this Agreement, “Good Reason” means the occurrence of any of the following events or conditions without your written consent:

(i) a material diminution in your base compensation (and you and the Company hereby agree that a diminution of your base
compensation of at least ten percent (10%) shall be required for such change to be considered a material diminution); 

(ii) a material change in the geographic location at which you must perform your duties (and you and the Company hereby agree that
a requirement that you be based at any place outside of at least a 30-mile radius of your place of employment as of the date of this agreement, except for reasonably required travel on the Company’s business, shall be required for such change
to be considered a material change); 
 (iii) a material diminution in your authority, duties or responsibilities; or

 (iv) any other action or inaction that constitutes a material breach by the Company or any successor or affiliate of
its obligations to you under this Agreement. 
 You must provide written notice to the Company of the occurrence of any of the
foregoing events or conditions without your written consent within thirty (30) days of the occurrence of such event. The Company or any successor or affiliate shall have a period of thirty (30) days to cure such event or condition
after receipt of written notice of such event from you. Any voluntary termination of your employment for “Good Reason” following such thirty (30) day cure period must occur no later than the date that is three (3) months
following the initial occurrence of one of the foregoing events or conditions without your written consent. 
 (f) Notice of
Termination. Any purported termination of your employment by the Company or by you (other than termination due to your death, which shall terminate your employment automatically) shall be communicated by a written notice of termination to the
other party hereto in accordance with Section 5. 

 (g) Other Terminations. If your employment is terminated by the Company for Cause or
by you without Good Reason, as a result of your death or disability, or if your employment is terminated for any reason prior to the occurrence of a Change in Control or more than twelve (12) months following the occurrence of a Change in
Control, the Company shall not have any other or further obligations to you under this Agreement (including any financial obligations). 
 3. Restrictive Covenants. 
 (a) Employee Proprietary Information and
Inventions Agreement. You acknowledge that you have executed and are subject to the provisions of the Company’s standard Employee Proprietary Information and Inventions Agreement (the “Employee Proprietary Information and
Inventions Agreement”), which agreement is incorporated herein by reference. 
 (b) Noncompetition. While
you are employed by the Company, you agree that you will not conduct business with any competitor of the Company, whether such business is conducted by you individually or as a principal, partner, member, stockholder, director, trustee, officer,
employee or independent contractor. 
 (c) Nonsolicitation. While you are employed by the Company, and for a period of
twelve (12) months after the date of your termination of employment with the Company, you agree that you will not in any manner, directly or indirectly (without the prior written consent of the Company) employ or solicit for employment for
himself or any other business entity (other than the Company) any individual who was, during the period of your employment with the Company or the twelve (12) month period following the date of your termination of employment, an employee,
officer, agent or representative of the Company. 
 (d) Remedies. If you breach or threaten to commit a breach of any of
the provisions of this Section 3, the Company shall have the right to cease all payments and benefits to you under Section 2, in addition to any other rights and remedies available to the Company under law or in equity. 

(e) Severability. If any court determines that any of the covenants set forth in this Section 3, or any part thereof, is
invalid or unenforceable, the remainder of the covenants set forth in this Section 3 shall not thereby be affected and shall be given full effect, without regard to the invalid portions. If any court determines that any of the covenants set
forth in this Section 3, or any part thereof, are unenforceable because of the duration of such provision or the area covered thereby, such court shall have the power to reduce the duration or area of such provision and, in its reduced form,
such provision shall then be enforceable and shall be enforced. You hereby waive any and all right to attack the validity of the covenants set forth in this Section 3 on the grounds of the breadth of their geographic scope or the length of
their term. 
 4. Successors; Binding Agreement. The Company shall require any successor (whether direct or indirect, by
purchase, merger, consolidation or otherwise) to all or substantially all of the business and/or assets of the Company to expressly assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be
required to perform it if no such succession had taken place. Unless expressly provided otherwise, “Company” as used herein shall mean the Company as defined in this Agreement and any

 
successor to its business and/or assets as aforesaid. This Agreement shall inure to the benefit of and be enforceable by you and your personal or legal representatives, executors, administrators,
successors, heirs, distributees, devisees and legatees. 
 5. Notices. For purposes of this Agreement, notices and all
other communications provided for in this Agreement shall be in writing and shall be deemed to have been duly given when delivered or mailed by United States certified or registered mail, return receipt requested, postage prepaid, addressed to the
respective addresses set forth on the first page of this Agreement, provided that all notices to the Company shall be directed to the attention of its General Counsel, or to such other address as either party may have furnished to the other in
writing in accordance herewith, except that notice of change of address shall be effective only upon receipt. 
 6.
Miscellaneous. No provision of this Agreement may be modified, waived or discharged unless such waiver, modification or discharge is agreed to in writing and signed by you and such officer as may be specifically designated by the Board. No
waiver by either party hereto at any time of any breach by the other party hereto of or compliance with, any condition or provision of this Agreement to be performed by such other party shall be deemed a waiver of similar or dissimilar provisions or
conditions at the same or at any prior or subsequent time. No agreements or representations, oral or otherwise, express or implied, with respect to the subject matter hereof have been made by either party which are not expressly set forth in this
Agreement. The validity, interpretation, construction and performance of this Agreement shall be governed by the laws of the State of California without regard to its conflicts of law principles. The section headings contained in this Agreement are
for convenience only, and shall not affect the interpretation of this Agreement. Any payments provided for hereunder shall be paid net of any applicable withholding required under federal, state or local law. 

7. Severability. The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or
enforceability of any other provision of this Agreement, which shall remain in full force and effect. 
 8. Counterparts.
This Agreement may be executed in several counterparts, each of which shall be deemed to be an original but all of which together shall constitute one and the same instrument. 
 9. Entire Agreement. Except with respect to the Notice of Grant of Restricted Stock Units (Performance Vesting) in connection with the Stock Awards granted on May 23, 2012 and August 28,
2012 (the “Grant Notice”), this Agreement and the Employee Proprietary Information and Inventions Agreement set forth the entire agreement of the parties hereto in respect of the payment of severance and the other matters
described herein and supersede all prior agreements, promises, covenants, arrangements, communications, representations or warranties, whether oral or written, by any officer, employee or representative of any party hereto, and any prior agreement
of the parties hereto in respect of the payment of severance, is hereby terminated and cancelled. Any of your rights hereunder shall be in addition to any rights you may otherwise have under benefit plans or agreements of the Company (other than
severance plans or agreements) to which you are a party or in which you are a participant, including, but not limited to, any Company sponsored employee benefit plans and stock options plans and any retention bonus agreements. The provisions of this
Agreement shall not in any way abrogate your rights under such other plans and agreements. Notwithstanding anything to the contrary set forth herein, in the event of any conflict between the terms of this Agreement and the terms of the Grant Notice,
the terms of the Grant Notice shall supersede the terms of this Agreement. 

 10. At-Will Employment. Nothing contained in this Agreement shall (a) confer
upon you any right to continue in the employ of the Company, (b) constitute any contract or agreement of employment, or (c) interfere in any way with the at-will nature of your employment with the Company. 

11. Arbitration; Dispute Resolution, Etc. Unless otherwise provided herein, in the event that there shall be a
dispute (a “Dispute”) among the parties arising out of or relating to this Agreement, or the breach thereof, the parties agree that such dispute shall be resolved by final and binding arbitration before a single arbitrator in
San Diego County, California, administered by the American Arbitration Association (the “AAA”), in accordance with the National Rules for the Resolution of Employment Disputes of the AAA (the “Rules”).
If the parties are unable to agree upon an arbitrator, one shall be appointed by the AAA in accordance with the Rules. The arbitrator’s decision shall be final and binding upon the parties, and may be entered and enforced in any court of
competent jurisdiction by either of the parties. The arbitrator shall have the power to grant temporary, preliminary and permanent relief, including without limitation, injunctive relief and specific performance. The Company will pay the direct
costs and expenses of the arbitration. You and the Company are responsible for your respective attorneys’ fees incurred in connection with enforcing this Agreement; however, you and the Company agree that, to the extent permitted by law,
the arbitrator may, in his or her discretion, award reasonable attorneys’ fees to the prevailing party; provided, further, that the prevailing party shall be reimbursed for such fees within forty-five (45) days following any
such award, but in no event later than the last day of your taxable year following the taxable year in which the fees were incurred; provided, further, that the parties’ obligations pursuant to this sentence shall terminate on the
tenth (10th) anniversary of your termination of
employment. This Section 11 is intended to be the exclusive method for resolving any and all claims by the parties against each other for payment of damages under this Agreement or relating to your employment; provided, however,
that neither this Agreement nor the submission to arbitration shall limit the parties’ right to seek provisional relief, including without limitation, injunctive relief, in any court of competent jurisdiction. Seeking any such relief shall not
be deemed to be a waiver of such party’s right to compel arbitration. Both you and the Company expressly waive your rights to a jury trial. 
 12. Code Section 409A. 
 (a) The compensation and benefits payable
under this Agreement, including without limitation the severance benefits described in Section 2 of this Agreement, are not intended to constitute “nonqualified deferred compensation” within the meaning of Section 409A of the
Internal Revenue Code of 1986, as amended (the “Code”), and, to the maximum extent permitted by applicable law, amounts payable to you pursuant to Section 2(a) shall be made in reliance upon Treasury Regulation
Section 1.409A-1(b)(9) (with respect to separation pay plans) or Treasury Regulation Section 1.409A-1(b)(4) (with respect to short-term deferrals). To the extent applicable, this Agreement shall be interpreted in accordance with Code
Section 409A and Department of Treasury regulations and other interpretive guidance issued thereunder. If the Company and you determine that any compensation or benefits payable under this Agreement may be or become subject to Code
Section 409A and related Department of Treasury guidance, the Company and you agree to amend this Agreement or adopt other policies or procedures (including amendments, policies and procedures with retroactive effect), or take such other
actions as the Company and you deem necessary or appropriate to (i) exempt the compensation and benefits payable under this Agreement from Code Section 409A and/or preserve the intended tax treatment of the compensation and benefits
provided with respect to this Agreement, or (ii) comply with the requirements of Code Section 409A and related Department of Treasury guidance. 

 (b) Notwithstanding anything herein to the contrary, to the extent any payments to you
pursuant to Section 2(a) are treated as non-qualified deferred compensation subject to Section 409A of the Code, then (i) no amount shall be payable pursuant to such section unless your termination of employment constitutes a
“separation from service” with the Company (as such term is defined in Treasury Regulation Section 1.409A-1(h) and any successor provision thereto) (a “Separation from Service”), and (ii) if at the time of
your Separation from Service you are a “specified employee” as defined in Section 409A of the Code, as determined by the Company in accordance with Section 409A of the Code, and the deferral of the commencement of any payments or
benefits otherwise payable hereunder as a result of such termination of employment is necessary in order to prevent any accelerated or additional tax under Section 409A of the Code, then the Company will defer the commencement of the payment of
any such payments or benefits hereunder (without any reduction in such payments or benefits ultimately paid or provided to you) until the date that is at least six (6) months following your Separation from Service (or the earliest date as is
permitted under Section 409A of the Code); provided, however, that the Company shall use its reasonable efforts to minimize such deferral and the dollar amount of payments or benefits so impacted. 

13. Survival. The respective obligations and benefits afforded to the Company and you as provided in Sections 2 (to the
extent that payments or benefits are owed as a result of a termination of employment that occurs during the term of this Agreement), 3, 4, 6, 11 and 13 shall survive the termination of this Agreement. 

[Signature page follows] 

 If this letter sets forth our agreement on the subject matter hereof, kindly sign and return
to the Company the enclosed copy of this letter, which shall then constitute our agreement on this subject. 
  

			
	Sincerely,
	
	THE ACTIVE NETWORK, INC.
		
	By:	 	 /s/ Kory Vossoughi

	Name:	 	Kory Vossoughi
	Its:	 	Chief Legal Officer

  

	
	Agreed and Accepted:
	
	 /s/ Sheryl Roland

 APPENDIX A 

RELEASE 
 (INDIVIDUAL TERMINATION) 
 THIS RELEASE is
made as of this     day of         ,         , by and between The Active Network, Inc. (the “Company”) and [Name]
(“Employee”). 
 Certain capitalized terms used in this Release are defined in that certain Change in
Control Agreement between the Company and me (as amended to date, the “Agreement”), the terms of which I have previously agreed to and of which this Release is a part. I have been offered the opportunity to receive the
severance benefits described in Section 2 of the Agreement from the Company to which I otherwise would not be entitled by executing the general release of claims set forth in this Release. 

I hereby confirm my obligations under Section 3 of the Agreement. 

I hereby for myself, and my heirs, agents, executors, successors, assigns and administrators (collectively, the “Related
Parties”), intending to be legally bound, do hereby REMISE, RELEASE AND FOREVER DISCHARGE the Company, its affiliates, subsidiaries, parents, joint ventures, and its and their officers, directors, shareholders, employees, predecessors,
and partners, and its and their respective successors and assigns, heirs, executors, and administrators (collectively, “Releasees”) from all causes of action, suits, debts, claims and demands whatsoever in law or in equity,
which I ever had, now have, or hereafter may have, or which the Related Parties may have, by reason of any matter, cause or thing whatsoever, from the beginning of my initial dealings with the Company or any predecessor to the date of this Release,
and particularly, but without limitation of the foregoing general terms, any claims arising from or relating in any way to my employment relationship with the Company or any predecessor, the terms and conditions of that employment relationship, and
the termination of that employment relationship, including, but not limited to, any claims arising under the Age Discrimination in Employment Act (“ADEA”), as amended, 29 U.S.C. ss. 621 et seq., the Older Worker’s
Benefit Protection Act, 29 U.S.C. ss. 626(f)(1), Title VII of The Civil Rights Act of 1964, as amended, 42 U.S.C. ss. 2000e et seq., the Civil Rights Act of 1871, the Civil Rights Act of 1991, the Americans with Disabilities Act, 42 U.S.C. ss.
12101–12213, the Rehabilitation Act, the Family and Medical Leave Act of 1993 (“FMLA”), 29 U.S.C. ss. 2601 et seq., the Fair Labor Standards Act, the Employee Retirement Income Security Act of 1974, as amended, the
National Labor Relations Act, as amended, the Immigration Reform and Control Act, as amended, the Worker Adjustment and Retraining Notification Act, as amended, the Occupational Safety and Health Act of 1970, as amended, and any other claims under
any federal, state or local common law, statutory, or regulatory provision, now or hereafter recognized, and any claims for attorneys’ fees and costs, but not including such claims to vested or accrued payments, benefits and other rights
provided to me under the Agreement and any employee benefit plan of the Company in which I am a participant. This Release is effective without regard to the legal nature of the claims raised and without regard to whether any such claims are based
upon tort, equity, implied or express contract or discrimination of any sort. Except as specifically provided herein, it is expressly understood and agreed that this Release will operate as a clear and unequivocal waiver by me of any claim for
accrued or unpaid wages, benefits or any other type of payment other than as provided under the Agreement and any employee benefit plan of the Company in which I am a participant. It is the intention of the parties to make this Release as broad and
as general as the law permits as to the claims released hereunder. 

 I ACKNOWLEDGE THAT I HAVE BEEN ADVISED OF AND AM FAMILIAR WITH THE PROVISIONS OF CALIFORNIA
CIVIL CODE SECTION 1542, WHICH PROVIDES AS FOLLOWS: 
 “A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR
DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH, IF KNOWN BY HIM OR HER, MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR.” 

BEING AWARE OF SAID CODE SECTION, I HEREBY EXPRESSLY WAIVE ANY RIGHTS I MAY HAVE THEREUNDER, AS WELL AS UNDER ANY OTHER STATUTES OR
COMMON LAW PRINCIPLES OF SIMILAR EFFECT. 
 I further agree and recognize that I have permanently and irrevocably severed my
employment relationship with the Company and that the Company has no obligation to employ me in the future. 
 The parties agree
and acknowledge that the Agreement, and the settlement and termination of any asserted or unasserted claims against the Releasees pursuant to the Agreement, are not and will not be construed to be an admission of any violation of any federal, state
or local statute or regulation, or of any duty owed by any of the Releasees to me. 
 I certify and acknowledge as follows:

 (a) That I have read the terms of this Release, and that I understand its terms and effects, including the fact that I have
agreed to RELEASE AND FOREVER DISCHARGE all Releasees from any legal action or other liability of any type related in any way to the matters released pursuant to this Release other than as provided in the Agreement and in this Release; 

(b) That I have signed this Release voluntarily and knowingly in exchange for the consideration described herein, which I acknowledge is
adequate and satisfactory to me and which I acknowledge is in addition to any other benefits to which I am otherwise entitled; 

(c) That I have been and am hereby advised in writing to consult with an attorney prior to signing this Release; 

(d) That I do not waive rights or claims that may arise after the date this Release is executed; 

(e) That neither the Company, nor any of its trustees, managers, employees, or attorneys, has made any representations to me concerning
the terms or effects of this Release other than those contained herein; 
 (f) That I have not filed, and will not hereafter
file, any claim against the Company relating to my employment and/or cessation of employment with the Company, or otherwise involving facts that occurred on or prior to the date that I have signed this Release, other than a claim that the Company
has failed to pay me the severance payments or benefits due under the Agreement or any employee benefit plan of the Company in which I am a participant; 

 (g) That if I commence, continue, join in, or in any other manner attempt to assert any
claim released herein against the Company, or otherwise violate the terms of this Release, (i) I will cease to have any further rights to severance payments or benefits from the Company, and (ii) I will be required to return any severance
payments or benefits made to me by the Company (together with interest thereon); and 
 (h) I acknowledge that I may later
discover facts different from or in addition to those which I know or believe to be true now, and I agree that, in such event, this Release will nevertheless remain effective in all respects, notwithstanding such different or additional facts or the
discovery of those facts. 
 I agree that neither I nor anyone acting by, through, under or in concert with me shall disparage
or otherwise communicate negative statements or opinions about the Company, its directors, officers, employees or business. Except as may be required by law, neither I, nor any member of my family, nor anyone else acting by, through, under or in
concert with me, will disclose to any individual or entity (other than my legal or tax advisors) the terms of the Agreement or this Release. 
 This Release may not be introduced in any legal or administrative proceeding, or other similar forum, except one concerning a breach of this Release. 

This Release and the Agreement constitute the complete understanding between me and the Company concerning the subject matter hereof. No
other promises or agreements will be binding unless signed by me and an authorized officer of the Company. 
 In the event that
any provision or portion of this Release will be determined to be invalid or unenforceable for any reason, the remaining provisions or portions of this Release will be unaffected thereby and will remain in full force and effect to the fullest extent
permitted by law. 
 The respective rights and obligations of the parties hereunder will survive termination of this Release to
the extent necessary for the intended preservation of such rights and obligations. 
 This Release will be governed by and
construed and interpreted in accordance with the laws of the State of California without reference to the principles of conflict of law. 

 FOR EMPLOYEES AGE 40 OR OLDER ONLY: 

I acknowledge that I am knowingly and voluntarily waiving and releasing any rights I may have under ADEA. I further acknowledge that I
have been advised by this writing, as required by the ADEA, that: (A) my waiver and release do not apply to any rights or claims that may arise on or after the date I execute this Release; (B) I have the right to consult with an attorney
prior to executing this Release; (C) I have 21 days to consider this Release (although I may choose to voluntarily execute this Release earlier); (D) I have 7 days following the execution of this Release by the parties to revoke the
Release; and (E) this Release will not be effective until the date upon which the revocation period has expired, which will be the eighth day after this Release is executed by me. 

 

			
	[NAME]
	
	  

		
	Date:	 	  

 APPENDIX B 

RELEASE 
 (GROUP TERMINATION) 
 THIS RELEASE is made as
of this     day of         ,         , by and between The Active Network, Inc. (the “Company”) and [Name]
(“Employee”). 
 Certain capitalized terms used in this Release are defined in that certain Change in
Control Agreement between the Company and me (as amended to date, the “Agreement”), the terms of which I have previously agreed to and of which this Release is a part. I have been offered the opportunity to receive the
severance benefits described in Section 2 of the Agreement from the Company to which I otherwise would not be entitled by executing the general release of claims set forth in this Release. 

I hereby confirm my obligations under Section 3 of the Agreement. 

I hereby for myself, and my heirs, agents, executors, successors, assigns and administrators (collectively, the “Related
Parties”), intending to be legally bound, do hereby REMISE, RELEASE AND FOREVER DISCHARGE the Company, its affiliates, subsidiaries, parents, joint ventures, and its and their officers, directors, shareholders, employees, predecessors,
and partners, and its and their respective successors and assigns, heirs, executors, and administrators (collectively, “Releasees”) from all causes of action, suits, debts, claims and demands whatsoever in law or in equity,
which I ever had, now have, or hereafter may have, or which the Related Parties may have, by reason of any matter, cause or thing whatsoever, from the beginning of my initial dealings with the Company or any predecessor to the date of this Release,
and particularly, but without limitation of the foregoing general terms, any claims arising from or relating in any way to my employment relationship with the Company or any predecessor, the terms and conditions of that employment relationship, and
the termination of that employment relationship, including, but not limited to, any claims arising under the Age Discrimination in Employment Act (“ADEA”), as amended, 29 U.S.C. ss. 621 et seq., the Older Worker’s
Benefit Protection Act, 29 U.S.C. ss. 626(f)(1), Title VII of The Civil Rights Act of 1964, as amended, 42 U.S.C. ss. 2000e et seq., the Civil Rights Act of 1871, the Civil Rights Act of 1991, the Americans with Disabilities Act, 42 U.S.C. ss.
12101–12213, the Rehabilitation Act, the Family and Medical Leave Act of 1993 (“FMLA”), 29 U.S.C. ss. 2601 et seq., the Fair Labor Standards Act, the Employee Retirement Income Security Act of 1974, as amended, the National Labor
Relations Act, as amended, the Immigration Reform and Control Act, as amended, the Worker Adjustment and Retraining Notification Act, as amended, the Occupational Safety and Health Act of 1970, as amended, and any other claims under any federal,
state or local common law, statutory, or regulatory provision, now or hereafter recognized, and any claims for attorneys’ fees and costs, but not including such claims to vested or accrued payments, benefits and other rights provided to me
under the Agreement and any employee benefit plan of the Company in which I am a participant. This Release is effective without regard to the legal nature of the claims raised and without regard to whether any such claims are based upon tort,
equity, implied or express contract or discrimination of any sort. Except as specifically provided herein, it is expressly understood and agreed that this Release will operate as a clear and unequivocal waiver by me of any claim for accrued or
unpaid wages, benefits or any other type of payment other than as provided under the Agreement and any employee benefit plan of the Company in which I am a participant. It is the intention of the parties to make this Release as broad and as general
as the law permits as to the claims released hereunder. 

 I ACKNOWLEDGE THAT I HAVE BEEN ADVISED OF AND AM FAMILIAR WITH THE PROVISIONS OF CALIFORNIA
CIVIL CODE SECTION 1542, WHICH PROVIDES AS FOLLOWS: 
 “A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR
DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH, IF KNOWN BY HIM OR HER, MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR.” 

BEING AWARE OF SAID CODE SECTION, I HEREBY EXPRESSLY WAIVE ANY RIGHTS I MAY HAVE THEREUNDER, AS WELL AS UNDER ANY OTHER STATUTES OR
COMMON LAW PRINCIPLES OF SIMILAR EFFECT. 
 I further agree and recognize that I have permanently and irrevocably severed my
employment relationship with the Company and that the Company has no obligation to employ me in the future. 
 The parties agree
and acknowledge that the Agreement, and the settlement and termination of any asserted or unasserted claims against the Releasees pursuant to the Agreement, are not and will not be construed to be an admission of any violation of any federal, state
or local statute or regulation, or of any duty owed by any of the Releasees to me. 
 The attachment to this Release includes a
listing of the ages and job titles of all employees of the Company who are eligible to receive the severance benefits described in the Agreement by signing a Release constituting a general release of all claims. 

I certify and acknowledge as follows: 
 (a) That I have read the terms of this Release, and that I understand its terms and effects, including the fact that I have agreed to RELEASE AND FOREVER DISCHARGE all Releasees from any legal action or
other liability of any type related in any way to the matters released pursuant to this Release other than as provided in the Agreement and in this Release; 
 (b) That I have signed this Release voluntarily and knowingly in exchange for the consideration described herein, which I acknowledge is adequate and satisfactory to me and which I acknowledge is in
addition to any other benefits to which I am otherwise entitled; 
 (c) That I have been and am hereby advised in writing to
consult with an attorney prior to signing this Release; 
 (d) That I do not waive rights or claims that may arise after the
date this Release is executed; 
 (e) That neither the Company, nor any of its trustees, managers, employees, or attorneys, has
made any representations to me concerning the terms or effects of this Release other than those contained herein; 
 (f) That I
have not filed, and will not hereafter file, any claim against the Company relating to my employment and/or cessation of employment with the Company, or otherwise involving facts that occurred on or prior to the date that I have signed this Release,
other than a claim that the Company has failed to pay me the severance payments or benefits due under the Agreement or any employee benefit plan of the Company in which I am a participant; 

 (g) That if I commence, continue, join in, or in any other manner attempt to assert any
claim released herein against the Company, or otherwise violate the terms of this Release, (i) I will cease to have any further rights to severance payments or benefits from the Company, and (ii) I will be required to return any severance
payments or benefits made to me by the Company (together with interest thereon); and 
 (h) I acknowledge that I may later
discover facts different from or in addition to those which I know or believe to be true now, and I agree that, in such event, this Release will nevertheless remain effective in all respects, notwithstanding such different or additional facts or the
discovery of those facts. 
 I agree that neither I nor anyone acting by, through, under or in concert with me shall disparage
or otherwise communicate negative statements or opinions about the Company, its directors, officers, employees or business. Except as may be required by law, neither I, nor any member of my family, nor anyone else acting by, through, under or in
concert with me, will disclose to any individual or entity (other than my legal or tax advisors) the terms of the Agreement or this Release. 
 This Release may not be introduced in any legal or administrative proceeding, or other similar forum, except one concerning a breach of this Release. 

This Release and the Agreement constitute the complete understanding between me and the Company concerning the subject matter hereof. No
other promises or agreements will be binding unless signed by me and an authorized officer of the Company. 
 In the event that
any provision or portion of this Release will be determined to be invalid or unenforceable for any reason, the remaining provisions or portions of this Release will be unaffected thereby and will remain in full force and effect to the fullest extent
permitted by law. 
 The respective rights and obligations of the parties hereunder will survive termination of this Release to
the extent necessary for the intended preservation of such rights and obligations. 
 This Release will be governed by and
construed and interpreted in accordance with the laws of the State of California without reference to the principles of conflict of law. 

 FOR EMPLOYEES AGE 40 OR OLDER ONLY: 

I acknowledge that I am knowingly and voluntarily waiving and releasing any rights I may have under ADEA. I further acknowledge that I
have been advised by this writing, as required by the ADEA, that: (A) my waiver and release do not apply to any rights or claims that may arise on or after the date I execute this Release; (B) I have the right to consult with an attorney
prior to executing this Release; (C) I have 45 days to consider this Release (although I may choose to voluntarily execute this Release earlier); (D) I have 7 days following the execution of this Release by the parties to revoke the
Release; (E) this Release will not be effective until the date upon which the revocation period has expired, which will be the eighth day after this Release is executed by me; and (F) I have received with this Release a detailed list of
the job titles and ages of all employees who were terminated in this group termination and the ages of all employees of the Company in the same job classification or organizational unit who were not terminated. 

 

			
	[NAME]
	
	  

		
	Date:	 	  

 ATTACHMENT TO RELEASE 

The following information is provided to comply with the Older Workers Benefit Protection Act. Capitalized terms used herein but not
defined will have the meanings given them in the General Release to which this Attachment is attached. Attached are the ages of all employees of Active Network, Inc. and its subsidiaries (collectively, the “Company”) who are
eligible to receive the severance benefits by signing a Release constituting a general release of all claims: 
  

	 	(1)	The decisional unit is the Company. 

  

	 	(2)	The attachment includes a listing of the ages and job titles of all employees of the Company who are eligible to receive the severance benefits by signing a Release
constituting a general release of all claims. 

 JOB CLASSIFICATION AND AGE OF EMPLOYEES 

ELIGIBLE FOR SEVERANCE BENEFITS 
  

					
	 Job Title
	 	 Selected Persons by Age
	 	 Age of Those Not Selected

for Termination

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00209-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00209-of-00352.parquet"}]]